Editorial: It's time to make organized colorectal cancer screening convenient and easy for patients

American Journal of Gastroenterology

Volumn 104, Issue 4, 2009, Pages 939-941

  Levin, Theodore R ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ENOXAPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN;

ADVANCED CANCER; BLEEDING DISORDER; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SCREENING; CARDIOVASCULAR RISK; CLINICAL EVALUATION; COLONOSCOPY; COLORECTAL CANCER; DRUG USE; HEALTH CARE; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH INSURANCE; HEART INFARCTION; HUMAN; IMMUNOCHEMISTRY; OCCULT BLOOD TEST; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; STROKE; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; DIFFERENTIAL DIAGNOSIS; GASTROINTESTINAL HEMORRHAGE; IMMUNOHISTOCHEMISTRY; MASS SCREENING; OCCULT BLOOD; ORGANIZATION AND MANAGEMENT; PROCEDURES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; COLORECTAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; GASTROINTESTINAL HEMORRHAGE; HUMANS; IMMUNOHISTOCHEMISTRY; MASS SCREENING; OCCULT BLOOD;

EID: 65449142518     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.18     Document Type: Review

References (21)

1. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2008: a review of current American Cancer Societ) Gnidelines and cancer screening issues. CA Cancer J Clin 2008;58:161-79.
2. Ries L, Melbert D, Krapchn M et al. SEER Cancer Statistics Review, 1975-2004. Natinnal Cancer Institute: Bethesda, MU, 2007.
3. Seeff LC, Manninen DL, Dnng PB et al. is there endnscnpic capacity tn prnvide colorectal cancer screening to the unscreened population in the United States? Gastroenterology 2004;127:1661-9.
4. DeNavas-Walt C, Proctor BD, Smith J In: Bureau USC (ed). Income, Pox erty. and Health Insurance Coverage in the United States: 2006. US Goxernment Printing Othce: Washington, DC. 2007.
5. Segnan N, Senore C, Andreoni B et al. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates. J Natl Cancer Inst 2005;97:347-57.
6. Benson V5, Patnick J, Davies AK et al. Colorectal cancer screening: a comparison of 35 initiatives in t7 countries. Tnt J Cancer 2008;122: 1357-67.
7. Parekh lvi, rendrick AM, Ladabaum U. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Aliment Pharmacol Ther 2008;27:697-712.
8. van Rossum LG, van Rim Ar. Eaheii RJ et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135:82-90.
9. Allison JE, Tekawa IS, Ransom LJ et al. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996;334:155-9.
10. Allison JE, Sakoda LC, Levsn TR et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J. NatI Cancer Inst 2007;99:1462-70.
11. Whitlock EP, Lin JS, Liles E et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:638-58.
12. Levi Z, Rozen P, Hazazi R et al. Sensitivity, but not specificity of a quantitative immunochemical fecal occult blood for neoplasia, is slightly increased by the use of low dose aspirin, NSAIDs, and anticoagulants. Am J Gastroenterol 2009;104:933-938 (this issue).
13. Blacker DJ, Wi)dicks EF, McClelland RL. Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology 2003;61:964-8.
14. Eisen GM, Baron TH, Dominitz JA et al. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc 2002;55:775-9.
15. Levin B, Lieberman DA, McFarland B et of Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008;134:1570-95.
16. Levin B, Lieberman DA, McFadand B et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008;58:130-60.
17. Morikawa T, Kato J, Yamaji Y et al. Sensitivity of immunochemical fecal occult blood test to small colorectal adenomas. Am J Gastroenterol 2007;102:2259-64.
18. Morikawa T, Kato J, Yamaji Y et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005;129:422-8.
19. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB et al. Evaluating lest strategies for colorectal cancer screening: a decision analysts for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:659-69.
20. Singh H, Turner D, Xue L et al. Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a to-year interval between colonoscopies. JAMA 2006;295:2366-73.
21. Stryker Sb Wolff BG, Culp CE et al. Natural history of untreated colonic polyps. Gastroenterology 1987;93:1009-13.